Results 151 to 160 of about 101,470 (368)

Adverse in‐hospital outcomes in patients with paraplegia who undergo radical prostatectomy

open access: yesBJU International, EarlyView.
Objective To test for the association between paraplegia and perioperative complications as well as in‐hospital mortality after radical prostatectomy (RP) for non‐metastatic prostate cancer. Patients and Methods We identified patients who underwent RP (National Inpatient Sample [NIS] 2000–2019), stratified according to paraplegia status.
Andrea Marmiroli   +23 more
wiley   +1 more source

Robotic-assisted laparoscopic radical cystectomy: surgical and oncological outcomes

open access: yesInternational Brazilian Journal of Urology, 2012
PURPOSE:Our first 91 consecutive cases undergoing a robotic assisted cystectomy were analyzed regarding perioperative outcomes, pathological stages and surgical complications.
Adrian Treiyer   +5 more
doaj   +1 more source

Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer

open access: yesJAMA Surgery, 2018
Importance Radical cystectomy is the guidelines-recommended treatment of muscle-invasive bladder cancer, but a resurgence of trimodal therapy has occurred.
S. Williams   +10 more
semanticscholar   +1 more source

Are UK and Australian Trained Urologists the Same?—Ahpra Thinks They Are

open access: yes
ANZ Journal of Surgery, EarlyView.
Kathryn McLeod, Richard Grills
wiley   +1 more source

Long‐term outcomes of a cascading salvage strategy for high‐risk non‐muscle‐invasive bladder cancer

open access: yesBJU International, EarlyView.
Objective To report long‐term oncological outcomes of patients with high‐risk non‐muscle‐invasive bladder cancer (HR‐NMIBC) undergoing bladder‐sparing therapy (BST) after bacillus Calmette–Guérin (BCG) failure. Patients and Methods We retrospectively reviewed patients with HR‐NMIBC treated from 2000 to 2025 with intravesical therapies after BCG failure,
Ian M. McElree   +5 more
wiley   +1 more source

Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer.

open access: yesJAMA Surgery, 2019
Importance Earlier studies on the cost of muscle-invasive bladder cancer treatments lack granularity and are limited to 180 days. Objective To compare the 1-year costs associated with trimodal therapy vs radical cystectomy, accounting for survival and ...
S. Williams   +13 more
semanticscholar   +1 more source

Zebrafish Xenograft Model for Predicting Cisplatin Efficacy in Muscle‐Invasive Bladder Cancer

open access: yesCancer Science, EarlyView.
This study establishes a zebrafish patient‐derived xenograft (zPDX) model optimized for predicting cisplatin sensitivity in muscle‐invasive bladder cancer. Through technical validation and correlation with clinical outcomes, the model demonstrated its potential as a rapid, cost‐effective platform for individualized chemotherapy response assessment ...
Yusuke Sugino   +16 more
wiley   +1 more source

In vitro functional properties of the rat bladder regenerated by the bladder acellular matrix graft. [PDF]

open access: yes, 1998
PurposeTo assess the response of rat urinary bladder regenerated by the homologous bladder acellular matrix graft (BAMG) to in vitro electrical and pharmacologic stimuli.Materials and methodsIn Sprague-Dawley rats, partial cystectomy (>50%) was ...
Dahiya, R   +5 more
core   +1 more source

Current Status and Future Perspectives of Molecular Residual Disease Testing in Genitourinary Cancers

open access: yesInternational Journal of Urology, EarlyView.
ABSTRACT While the clinical outcome for patients with resectable solid tumors has improved in recent years, the risk of postoperative recurrence underscores the need for effective monitoring in cancer patients. Molecular residual disease (MRD) refers to the presence of microscopic cancer that remains undetectable on conventional imaging or pathology ...
Taigo Kato   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy